Wegovy pill vs. injection: formulation changes the decision

Wegovy tablets and Wegovy injection are FDA-approved semaglutide products with different routes and product instructions; the tablet was approved in late 2025. Compare the named products and their uses in FDA Wegovy tablets approval review and FDA Wegovy injection prescribing information. Clinical similarity between Wegovy tablets and Wegovy injection does not make their instructions interchangeable. Ask why Wegovy tablets or Wegovy injection fits the documented diagnosis.

The FDA review identifies the oral tablet as a separate application and compares its labeling with the injection. That is stronger evidence of product status than an old article saying no oral Wegovy exists. Route choice is not merely convenience: a patient must be able to follow the particular product’s administration requirements, and the clinician must use the correct indication and label. Do not transfer trial results or dose numbers between routes. FDA warns about unapproved GLP-1 products marketed as substitutes for approved medicines. See FDA concerns with unapproved GLP-1 drugs. Evidence for Wegovy tablets cannot automatically establish a result with Wegovy injection.

Some people may prefer to avoid injections; others may value a less frequent administration schedule. The real choice also depends on clinical suitability, insurance, routine, interactions and tolerance. The FDA has cautioned against promotional claims implying that the pill is superior to other GLP-1 treatments without supporting data. Check the specific warnings and patient instructions in FDA Wegovy tablets approval review and FDA Wegovy injection prescribing information. Let the prescriber direct any change from Wegovy tablets to Wegovy injection; follow the dispensed package.

Ask the prescriber what daily routine the tablet requires, how injection training works for the injection, and how missed treatments are handled. Confirm which version the pharmacy will actually dispense. For Wegovy tablets or Wegovy injection, confirm the pharmacy, coverage and reassessment date. For a compounded form of Wegovy tablets, request the medical rationale and directly applicable evidence.

The tablet’s daily routine can matter as much as avoiding a needle: ask whether morning timing, food and other medicines fit your life. For an injection, ask how training and travel supplies are handled. Do not compare trial percentages without checking which formulation, indication and population generated each number. A patient changing routes should ask the prescriber to write a fresh plan and the pharmacist to review the dispensed package. Tablet and injection labels may share semaglutide yet differ in timing and practical handling. The FDA approval of the tablet does not make it a simple at-home replacement for an injection.